Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Medical Excellence Capital, LLC (MEC) is an early-stage life sciences venture fund founded in 2020 and based in the United States. The firm focuses on advancing precision health innovations and has an active portfolio of 6 companies. MEC targets transformative technologies that address significant medical challenges.
MEC invests in company creation, seed, Series A, and Series B opportunities within the life sciences sector. Their investment areas include artificial intelligence in drug discovery, cell and gene therapy, precision medicine, regenerative medicine, and synthetic biology.
Notable companies in MEC's portfolio include Aspen Neuroscience, which develops personalized cell therapies for Parkinson's disease; Avilar Therapeutics, focused on extracellular protein degraders; and Immunitas Therapeutics, which specializes in precision immunotherapy for cancer.
Email info@medexcelcap.com with your deck to pitch Medical Excellence Capital.
MEC often leads investment rounds, particularly in seed and Series A stages, to help shape the direction of their portfolio companies.
MEC is open to follow-on investments, especially for companies that demonstrate significant progress and alignment with their focus areas.
The specific size of MEC's current fund is not publicly disclosed, but they actively manage investments across multiple early-stage life sciences companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.